In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Rima Fawaz about the role of GLP-1 receptor agonists in the treatment of children and adolescents with metabolic dysfunction-associated steatotic liver disease or MASLD (the artist formerly known as non-alcoholic fatty liver disease or NAFLD). We discuss what these medications do, what we know about their positive and negative effects, and how we should be using them based on the current literature. Dr. Fawaz is Medical Director of Pediatric Hepatology and Liver Transplantation at Yale New Haven Children's Hospital and Associate Professor at Yale School of Medicine.

Learning Objectives:

Understand the therapeutic and potential adverse effects of GLP-1 receptor agonists.
Recognize that the foundation of obesity and MASLD treatment remains lifestyle changes focused on diet and exercise.
Recognize the role that GLP-1 receptor agonists will play in our care for children and adolescents with obesity and MASLD.

Links:

Abou Jaoudeh RAR, et al. Pharmacological management of pediatric metabolic dysfunction-associated liver disaese. J Pediatr Gastroenterol Nutr. 2025.

Support the show

This episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!

As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.

Check out our merch website!

Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.

Click here to support the show.

Rima Fawaz - GLP-1 Agonists for MASLD

Powered by Wave AI